Feline chronic kidney disease (CKD) is one of the largest unmet medical needs in companion animal health, affecting an estimated 30-40% of cats over the age of 10. Zoetis identified the feline CKD opportunity as a strategic pivot for 2026 and beyond, estimating a $3-4 billion addressable market over the next decade. Current management — fluid therapy, phosphorus binders, and prescription renal diets from Royal Canin (Mars), Hill's Pet Nutrition (Colgate), and Purina (Nestlé) — leaves significant therapeutic gaps. Emerging therapeutics include hypoxia-inducible factor stabilizers, anti-inflammatory mAbs, and novel small molecules targeting renal fibrosis. Diagnostic innovation including IDEXX SDMA testing has expanded earlier disease detection, opening a longer therapeutic window.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Feline CKD Market Size, Growth and Forecast 2025-2035
• Disease Epidemiology — Prevalence, Stages, and Progression
• Diagnostic Innovation — IDEXX SDMA, Creatinine, and Emerging Biomarkers
• Therapeutic Pipeline — HIF Stabilizers, Anti-Fibrotics, mAbs
• Renal Diets — Royal Canin, Hill's, Purina Veterinary Lines
• Fluid Therapy and Phosphorus Binders — Established Therapeutics
• Anti-Hypertensives and Proteinuria Management
• Owner Compliance and Pet Quality of Life Considerations
• Investment and Partnership Opportunities — Licensing, Pipeline Acquisition
• Veterinary Specialist Network and Referral Dynamics
• Market Challenges and Risks — Diagnostic Adoption, Pricing, Reimbursement
Table of Contents
1. Executive Summary
2. Market Overview
3. Feline CKD Market Size, Growth and Forecast 2025-2035
4. Disease Epidemiology
5. Diagnostic Innovation
6. Therapeutic Pipeline
7. Renal Diets
8. Fluid Therapy and Phosphorus Binders
9. Anti-Hypertensives and Proteinuria Management
10. Owner Compliance and Quality of Life
11. Veterinary Specialist Network
12. Regional Analysis
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Feline CKD Market Size and Forecast 2025-2035
Table 2. Disease Prevalence by Cat Age and Stage
Table 3. Diagnostic Test Sales — SDMA, Creatinine, Emerging Markers
Table 4. Therapeutic Pipeline by Supplier and Mechanism of Action
Table 5. Renal Diet Sales by Manufacturer 2023-2025
Table 6. Phosphorus Binder Sales by Brand 2023-2025
Table 7. Anti-Hypertensive and Proteinuria Therapeutics — Sales by Supplier
Table 8. Owner Compliance Rates by Therapeutic Type
Table 9. Veterinary Internal Medicine Specialist Network
Table 10. Investment Activity in Feline CKD Therapeutics 2023-2026
Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Elanco Animal Health
Hill's Pet Nutrition
IDEXX Laboratories
Merck Animal Health
Purina
Royal Canin
Vetoquinol
Virbac
Zoetis
